Reading RMTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RMTI free→Reading RMTI? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track RMTI free→
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and management's recent track record has been steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Peer multiples imply a price about 74% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples, but recent financials are weak or earnings quality is fragile. Key factors to watch include guidance changes and sector trends, as these can significantly impact the stock's trajectory. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $0.68. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $0.64 RMTI trades at 0× p/s, below its 3× p/s peer median. Our $2.91 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 78% below a flat-multiple fair value, below our forecast of about -26%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted -0.49x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
3 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $-0.03 → $-0.03 (+0.0% / 30d). 0 raised, 2 cut, 2 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 147.0% above current price.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$200.
How much price usually moves either way.
On a bad day, this stock has moved -$680.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $6,598.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: The earnings report will show how the company is doing. It can affect investor trust and stock value.
Confirms one read:Announcement of the next earnings date with positive guidance or results.
Confirms the other:The next earnings date is announced. Negative guidance or bad results may follow.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for RMTI yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On May 8, 2026, Rockwell Medical, Inc. (the “Company”) received written notice (the “Notice”) from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities maintain a mi…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
RMTI Rockwell Medical Inc | Typical Show detailsSector percentile: 65 of 100 | inexpensive | high |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 89 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 75 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 63 of 100 | full | low |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Rockwell Medical aims to achieve positive operating cash flow by the end of 2026.
Rockwell Medical targets a gross margin range of 18% to 22% for the fiscal year 2026.
Rockwell Medical aims for adjusted EBITDA between $1 million and $2 million for 2026.
Why it matters: A shift in revenue growth could signal a change in the company's market position. Investors will want to see if the growth rate improves or continues to decline.
Confirms one read:Revenue growth is speeding up again. This shows stronger demand.
Confirms the other:Revenue growth is slowing down. This shows ongoing market problems.
and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.
and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing. Forward-Looking Statements Certain statements contained in the press release filed herewith may constitute "forward-looking s…
and Exhibit 99.1 incorporated in this Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall such information or Exhibit 99.1 be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such a filing.